CTOR gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of CTOR have multiple concerns. CTOR is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CTOR has reported negative net income.
CTOR had a negative operating cash flow in the past year.

1.2 Ratios

CTOR's Return On Assets of -24.53% is fine compared to the rest of the industry. CTOR outperforms 71.43% of its industry peers.
Looking at the Return On Equity, with a value of -55.19%, CTOR is in the better half of the industry, outperforming 64.38% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.53%
ROE	-55.19%
ROIC	N/A

ROA(3y)-24.09%

ROA(5y)N/A

ROE(3y)-34.59%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTOR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CTOR has more shares outstanding
The debt/assets ratio for CTOR is higher compared to a year ago.

2.2 Solvency

CTOR has an Altman-Z score of -0.94. This is a bad value and indicates that CTOR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.94, CTOR is in line with its industry, outperforming 56.38% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that CTOR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, CTOR is doing worse than 61.71% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-0.94

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.56 indicates that CTOR may have some problems paying its short term obligations.
CTOR has a worse Current ratio (0.56) than 89.52% of its industry peers.
CTOR has a Quick Ratio of 0.56. This is a bad value and indicates that CTOR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTOR has a Quick ratio of 0.11. This is amonst the worse of the industry: CTOR underperforms 93.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.56
Quick Ratio	0.11

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CTOR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.75%.

EPS 1Y (TTM)-8.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%80.09%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

CTOR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 89.47% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y115%

EPS Next 2Y89.47%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTOR. In the last year negative earnings were reported.
CTOR is valuated rather expensively with a Price/Forward Earnings ratio of 21.37.
Based on the Price/Forward Earnings ratio, CTOR is valued cheaper than 93.33% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 25.83. CTOR is around the same levels.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	21.37

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTOR's earnings are expected to grow with 89.47% in the coming years. This may justify a more expensive valuation.